<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Tipranavir: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i1055.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i1055.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i1055.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a> &gt; <a href="41001i391.htm">Antivirals</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i1088.htm" title="Previous: Adefovir">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i1005.htm" title="Next: Atazanavir">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i1055">Tipranavir</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Tipranavir</b>
          has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i907.htm" name="_907">Abacavir</a></td><td class="cBV"><b> tipranavir reduces plasma concentration of abacavir </b></td><td></td></tr><tr><td><a href="41001i110.htm">Antacids</a></td><td>absorption of  tipranavir reduced by antacids </td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr><tr><td><a href="41001i1217.htm" name="_1217">Apixaban</a></td><td>avoidance of  tipranavir advised by manufacturer of apixaban </td><td></td></tr><tr><td><a href="41001i937.htm" name="_937">Artemether with Lumefantrine</a></td><td>caution with  tipranavir advised by manufacturer of artemether/lumefantrine </td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td>plasma concentration of  tipranavir increased by atazanavir (also plasma concentration of atazanavir reduced)</td><td></td></tr><tr><td><a href="41001i601.htm" name="_601">Atorvastatin</a></td><td class="cBV"><b> tipranavir increases plasma concentration of atorvastatin (increased risk of myopathy—reduce dose of atorvastatin)</b></td><td></td></tr><tr><td><a href="41001i943.htm">Bosentan</a></td><td>manufacturer of  tipranavir advises avoid concomitant use with bosentan </td><td></td></tr><tr><td><a href="41001i87.htm">Buprenorphine</a></td><td>plasma concentration of  tipranavir possibly reduced by buprenorphine </td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>plasma concentration of  tipranavir possibly reduced by carbamazepine </td><td></td></tr><tr><td><a href="41001i168.htm" name="_168">Clarithromycin</a></td><td class="cBV"><b> tipranavir increases plasma concentration of clarithromycin (reduce dose of clarithromycin in renal impairment), also plasma concentration of tipranavir increased by clarithromycin</b></td><td></td></tr><tr><td><a href="41001i1076.htm" name="_1076">Darifenacin</a></td><td>avoidance of  tipranavir advised by manufacturer of darifenacin </td><td></td></tr><tr><td><a href="41001i397.htm" name="_397">Didanosine</a></td><td class="cBV"><b> tipranavir reduces plasma concentration of didanosine </b></td><td>Antacids in tablet formulation may affect absorption of other drugs</td></tr><tr><td><a href="41001i914.htm" name="_914">Esomeprazole</a></td><td class="cBV"><b> tipranavir reduces plasma concentration of esomeprazole </b></td><td></td></tr><tr><td><a href="41001i1135.htm" name="_1135">Etravirine</a></td><td class="cBV"><b> tipranavir reduces plasma concentration of etravirine , also plasma concentration of tipranavir increased (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i301.htm">Fluconazole</a></td><td>plasma concentration of  tipranavir increased by fluconazole </td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr><tr><td><a href="41001i1019.htm" name="_1019">Fosamprenavir</a></td><td class="cBV"><b> tipranavir reduces plasma concentration of fosamprenavir </b></td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i922.htm" name="_922">Lopinavir</a></td><td class="cBV"><b> tipranavir reduces plasma concentration of lopinavir </b></td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i451.htm">Metoprolol</a></td><td class="cBV"><b>manufacturer of  tipranavir advises avoid concomitant use with metoprolol for heart failure</b></td><td></td></tr><tr><td><a href="41001i752.htm" name="_752">Omeprazole</a></td><td class="cBV"><b> tipranavir reduces plasma concentration of omeprazole </b></td><td></td></tr><tr><td><a href="41001i824.htm" name="_824">Quetiapine</a></td><td class="cBV"><b> tipranavir possibly increases plasma concentration of quetiapine—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i341.htm" name="_341">Quinine</a></td><td class="cBV"><b> tipranavir possibly increases plasma concentration of quinine (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i1147.htm" name="_1147">Ranolazine</a></td><td class="cBV"><b> tipranavir possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i200.htm" name="_200">Rifabutin</a></td><td class="cBV"><b> tipranavir increases plasma concentration of rifabutin (reduce dose of rifabutin)</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  tipranavir possibly reduced by rifampicin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1136.htm" name="_1136">Rivaroxaban</a></td><td>avoidance of  tipranavir advised by manufacturer of rivaroxaban </td><td></td></tr><tr><td><a href="41001i974.htm" name="_974">Rosuvastatin</a></td><td class="cBV"><b> tipranavir possibly increases plasma concentration of rosuvastatin—manufacturer of rosuvastatin advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i727.htm">Salmeterol</a></td><td>manufacturer of  tipranavir advises avoid concomitant use with salmeterol </td><td></td></tr><tr><td><a href="41001i791.htm" name="_791">Saquinavir</a></td><td class="cBV"><b> tipranavir reduces plasma concentration of saquinavir </b></td><td></td></tr><tr><td><a href="41001i605.htm" name="_605">Simvastatin</a></td><td class="cBV"><b> tipranavir possibly increases plasma concentration of simvastatin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>plasma concentration of  tipranavir possibly reduced by St John's wort—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i946.htm" name="_946">Telithromycin</a></td><td class="cBV"><b>avoidance of concomitant  tipranavir in severe renal and hepatic impairment advised by manufacturer of telithromycin </b></td><td></td></tr><tr><td><a href="41001i967.htm">Vardenafil</a></td><td>manufacturer of  tipranavir advises caution with vardenafil </td><td></td></tr><tr><td><a href="41001i1134.htm">Vitamin E</a></td><td>increased risk of bleeding when  tipranavir given with high doses of vitamin E </td><td></td></tr><tr><td><a href="41001i403.htm" name="_403">Zidovudine</a></td><td class="cBV"><b> tipranavir reduces plasma concentration of zidovudine </b></td><td>Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</td></tr></tbody></table><p>Tipranavir belongs to <b>Antivirals</b>
          but <b>Antivirals</b>
          has no interactions information.
        </p></div><?highlighter on?><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i1088.htm">Previous: Adefovir</a> | <a class="top" href="41001i1055.htm#">Top</a> | <a accesskey="]" href="41001i1005.htm">Next: Atazanavir</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>